1. Introduction {#sec1-molecules-23-00199}
===============

Antimicrobial resistance has been listed by the World Health Organization (WHO) as one of the biggest threats to global health today \[[@B1-molecules-23-00199]\]. The antibiotic resistance crisis has been attributed to the overuse and misuse of these medications, as well as a lack of new drug development by the pharmaceutical industry due to reduced economic incentives and challenging regulatory requirements \[[@B2-molecules-23-00199],[@B3-molecules-23-00199],[@B4-molecules-23-00199],[@B5-molecules-23-00199],[@B6-molecules-23-00199]\]. Over the past decade, it has become apparent that several highly resistant bacterial pathogens have acquired clever mechanisms to negate the effectiveness of numerous therapeutic agents \[[@B7-molecules-23-00199]\]. *Staphylococcus aureus* is one bacterial pathogen that has emerged as a significant concern to healthcare professionals worldwide. In this sense, isolated strains of *S. aureus* have exhibited resistance to several classes of antibacterial drugs, including β-lactam antibiotics \[[@B8-molecules-23-00199]\], macrolides \[[@B9-molecules-23-00199]\], fluoroquinolones \[[@B10-molecules-23-00199],[@B11-molecules-23-00199],[@B12-molecules-23-00199]\], glycopeptides \[[@B13-molecules-23-00199]\] and oxazolidinones \[[@B14-molecules-23-00199]\]. *Enterococci* were previously considered commensal organisms of little clinical importance but have emerged as serious nosocomial pathogens responsible for e.g. endocarditis and infections of the urinary tract, bloodstream, meninges, wounds and the biliary tract \[[@B15-molecules-23-00199]\]. Recent surveillance data indicate that *Enterococcus* is the third most commonly isolated nosocomial pathogen (12% of all hospital infections), only behind coagulase-negative *Staphylococcus* and *Staphylococcus aureus* \[[@B16-molecules-23-00199]\]. The clinical importance of the genus *Enterococcus* is directly related to its antibiotic resistance, which contributes to the risk of colonization and infection. *Enterococci* are intrinsically resistant to many commonly used antimicrobial agents (penicillins, ampicillins, cephalosporins, clindamycin) and exhibit native resistance to clinically achievable concentrations of aminoglycosides. Although *E. faecalis* is naturally resistant to quinupristin-dalfopristin, this combination is highly active against *E. faecium* strains that lack specific resistance determinants. *Enterococci* are tolerant to the (normally) bactericidal activity of cell-wall active agents, such as β-lactam antibiotics and vancomycin. Tolerance implies that the bacteria can be inhibited by clinically achievable concentrations of the antibiotic but will only be killed by concentrations far in excess of the inhibitory concentration \[[@B17-molecules-23-00199]\]. The emergence of multi-resistant *E. faecalis* strains, complicating the treatment, means that it is important to search for and identify new treatment strategies.

All the information mentioned above highlights the urgent need to develop novel antibacterial agents devoid of cross-resistance to marketed antibiotics.

The use of privileged structures in drug discovery has proven to be an effective strategy allowing the generation of innovative hits⁄leads and successful optimization processes \[[@B18-molecules-23-00199],[@B19-molecules-23-00199]\]. Coumarins are considered to be privileged structures due to their broad range of biological properties including anticoagulant \[[@B20-molecules-23-00199]\], anti-neurodegenerative \[[@B21-molecules-23-00199]\], antioxidant \[[@B22-molecules-23-00199]\], anticancer \[[@B23-molecules-23-00199]\] and antimicrobial activities \[[@B24-molecules-23-00199],[@B25-molecules-23-00199],[@B26-molecules-23-00199],[@B27-molecules-23-00199],[@B28-molecules-23-00199]\]. These interesting properties of coumarins can be ascribed to the chemical attributes of the 2*H*-chromen-2-one core; its aromatic ring can establish a series of hydrophobic, π--π, CH--π and cation--π interactions and the two oxygen atoms in the lactone ring can hydrogen-bond to a series of amino acid residues in different classes of enzymes and receptors. Additionally, the double bond in the lactone helps to make the planar system, allows charge delocalization between the carbonyl group of the lactone and the aromatic ring and confers the characteristic fluorescence of this class of compounds.

On the other hand, 1,2,3-triazoles are nitrogen heterocycles capable of forming hydrogen bonds, which improves their solubility and ability to interact with biomolecular targets \[[@B29-molecules-23-00199]\]. The 1,2,3-triazoles are highly stable to metabolic degradation, compared to other compounds containing three adjacent nitrogen (N) atoms \[[@B29-molecules-23-00199]\]. The triazoles have been used for broad therapeutic applications due to their diverse biological activities \[[@B30-molecules-23-00199]\], i.e. antimicrobial \[[@B31-molecules-23-00199],[@B32-molecules-23-00199],[@B33-molecules-23-00199]\], antiviral \[[@B34-molecules-23-00199]\], anti-inflammatory \[[@B35-molecules-23-00199]\], analgesic \[[@B35-molecules-23-00199]\], anticancer \[[@B36-molecules-23-00199],[@B37-molecules-23-00199],[@B38-molecules-23-00199]\], antifungal \[[@B39-molecules-23-00199]\] and anticonvulsant \[[@B40-molecules-23-00199]\] activities.

Taking into consideration the antimicrobial activity shown by some coumarins and 1,2,3-triazols mentioned above and as a continuation of our project on searching for new antibacterial molecules \[[@B41-molecules-23-00199],[@B42-molecules-23-00199],[@B43-molecules-23-00199],[@B44-molecules-23-00199],[@B45-molecules-23-00199]\], we envisaged that the linkage of coumarin and 1,2,3-triazole pharmacophores through --OCH~2~-- or --NCH~2~-- linkers would generate novel hybrid molecules with promising antibacterial activities.

Therefore, we herein report the synthesis and antibacterial activity of coumarin-1,2,3-triazole conjugates with varied alkyl, phenyl and heterocycle moieties at C-4 of the triazole nucleus in order to evaluate their contribution to the antimicrobial activity.

2. Results and Discussion {#sec2-molecules-23-00199}
=========================

2.1. Chemistry {#sec2dot1-molecules-23-00199}
--------------

The required acetylenic dipolarophiles **3** and **6** were obtained as shown in [Scheme 1](#molecules-23-00199-sch001){ref-type="scheme"}. Thus, the treatment of 4-hydroxy-coumarin (**1**) with 3-bromoprop-1-yne (**2**) employing potassium carbonate in anhydrous acetone yielded the *O*-propargylated coumarin (**3**) in 55% yield. The *N*-propargylated coumarin (**6**) was obtained in 63% yield from 4-bromo-coumarin (**4**) through nucleophilic substitution with prop-2-yn-1-amine (**5**) in dimethylformamide (DMF).

The 4-substituted 1,2,3-triazole-coumarin derivatives were synthesized using a copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition reaction \[[@B46-molecules-23-00199]\] of the corresponding *O*-propargylated coumarin (**3**) or *N*-propargylated coumarin (**6**) with alkyl or aryl azides ([Scheme 2](#molecules-23-00199-sch002){ref-type="scheme"}).

Azides **7a**--**7j** were prepared from the corresponding boronic acids and sodium azide, in the presence of CuSO~4~ in ethanol (EtOH), at room temperature ([Table 1](#molecules-23-00199-t001){ref-type="table"} and [Scheme 3](#molecules-23-00199-sch003){ref-type="scheme"}) \[[@B47-molecules-23-00199],[@B48-molecules-23-00199]\].

Azides **7k**--**7m** were obtained from the corresponding alkyl bromide or aryl bromide and sodium azide in DMF ([Table 2](#molecules-23-00199-t002){ref-type="table"} and [Scheme 4](#molecules-23-00199-sch004){ref-type="scheme"}) \[[@B49-molecules-23-00199],[@B50-molecules-23-00199]\].

Following the reaction shown in [Scheme 2](#molecules-23-00199-sch002){ref-type="scheme"} and using azides **7a**--**7m**, compounds **8a**--**8m** and **9a**--**9m** were obtained as illustrated in [Figure 1](#molecules-23-00199-f001){ref-type="fig"}.

As can be seen, two isosteric series of coumarin derivatives were obtained (X=O, X=NH). Each series presents different substituents at the triazole moiety in order to evaluate their influence on the antimicrobial activity. Thus, coumarin derivatives with an aromatic ring having electron-donating groups or electron-withdrawing groups were prepared (**8a**--**8h**, **9a**--**9h**). Coumarin-triazole derivatives with alkyl moieties (**8k**, **9k**, **8l**, **9l**) and coumarin-indole hybrids (**8i**, **9i**) were synthesized as well. Moderate yields were obtained with aromatic azides while the use of the more stable aliphatic azides (**7k**, **7l** and **7m**) led to high yields, in agreement with the more favourable HOMO of the dipole in the 1,3-dipolar cycloaddition. The structures of all adducts were determined by spectroscopic studies. All of them showed the characteristic proton of the triazol ring in the ^1^H-NMR spectral region between δ 7.63 and 9.31. The hydrogen of the coumarin nucleus was detected as a singlet at δ 5.18--6.22 and the methylene hydrogens in the oxygenated series appeared as a singlet at δ 5.35--5.59 and as a doublet at δ 4.66--4.46 (*J* = 5.6 Hz) in the nitrogenated series.

The best yields were obtained from the *N*-propargylated coumarin (**6**) and from the aliphatic azides (**7k**, **7l** and **7m**).

2.2. Biology {#sec2dot2-molecules-23-00199}
------------

Since some coumarins and 1,2,3-triazoles have shown potential as antibacterial drugs \[[@B41-molecules-23-00199],[@B42-molecules-23-00199],[@B43-molecules-23-00199],[@B44-molecules-23-00199],[@B45-molecules-23-00199],[@B51-molecules-23-00199]\], these combined pharmacophores could offer some advantages e.g. in overcoming drug resistance as well as improving their biological potency.

The in vitro antimicrobial activity of the novel coumarin-1,2,3-triazole conjugates was tested against the yeast *Candida albicans,* Gram-positive bacteria *Staphylococcus aureus* and *Enterococcus faecalis* and Gram-negative bacteria *Escherichia coli*, *Klebsiella pneumonia* and *Pseudomonas aeruginosa*. The minimum inhibitory concentrations (MICs) were determined and given in [Table 3](#molecules-23-00199-t003){ref-type="table"}. As can be seen, most of the coumarin-triazole hybrids did not exhibit considerable activity against the tested microorganisms. The best results were obtained with conjugates **8a**, **8b**, **8f**, **9h** and **9k**, which displayed promising activity against *Enterococcus faecalis* at MICs ranging from 12.5 to 50.0 µg/mL. Compound **8b** having a 2-OMe--Ph group attached at the triazol nucleus and an --OCH~2~-- linker was the best of the series, while the corresponding isoster **9b** (--NHCH~2~--) turned out to be 64-fold less active than **8b**. The position of the OMe group in the phenyl ring also plays an important role in the activity, since compounds **8c** (3-OMe--Ph) and **8d** (4-OMe--Ph) showed an 8- and 16-fold lower antibacterial activity, respectively, than **8b**. In the nitrogenated series, compounds **9h** (3-NO~2~--Ph) and **9k** having an undecyl chain showed the best activities.

In other studies, menthyl 1,4-disubstituted 1,2,3-triazole derivatives of hydroxybenzaldehydes, phenols and bile acids showed a strong inhibitory effect against *E. faecium* with the minimum inhibitory concentration (MIC) values in the range of 1--3 μM \[[@B52-molecules-23-00199]\]. Kant and co-workers reported that 1,2,3-triazole linked chalcone and flavone hybrids showed activity against Gram-positive bacteria (*Staphylococcus aureus*, *Enterococcus faecalis*) and Gram-negative bacteria (*Escherichia coli*, *Pseudomonas aeruginosa*, *Shigella boydii*, *Klebsiella pneumoniae*) with MIC values in the range of 6.25--100 µg/mL \[[@B53-molecules-23-00199]\]. In turn, 1,2,4-triazolo\[3,4a\]phthalazine derivatives showed inhibitory activity against *Staphylococcus aureus* (MIC 16--128 µg/mL) \[[@B54-molecules-23-00199]\].

In order to verify if the newly synthesized triazoles could be considered as potential antimicrobial therapeutics, the most active compounds, namely **8a**, **8b**, **8f**, **9h** and **9k** were examined in terms of their haemolytic activity against human erythrocytes. The results are shown in [Figure 2](#molecules-23-00199-f002){ref-type="fig"}.

Compounds **8b**, **8f** and **9h** exhibit minimal toxicity towards human blood cells (1.6--3.1% of lysed cells) in MIC. Although compound **8b** appears to be the most active antimicrobial agent, simultaneously it moderately affects the erythrocytes (6.9% of lysed cells) in MIC. The presence of an undecyl chain in the triazole ring (**9k**) results in a drastic increase in the haemolytic activity (94% of lysed cells) in MIC.

3. Materials and Methods {#sec3-molecules-23-00199}
========================

3.1. Compounds Synthesis {#sec3dot1-molecules-23-00199}
------------------------

### 3.1.1. General Experimental Procedures {#sec3dot1dot1-molecules-23-00199}

IR spectra were obtained using a Fourier Transform Infrared spectrometer. NMR spectra were recorded in CDCl~3~ or DMSO at 500 or 600 MHz for ^1^H NMR and 125 or 150 MHz for ^13^C-NMR. Chemical shifts are given in (δ) parts per million and coupling constants (*J*) in hertz (Hz). ^1^H- and ^13^C-spectra were referenced using the solvent signal as an internal standard. Melting points were taken on a capillary melting point apparatus and are uncorrected. Microwave reactions were conducted in sealed glass vessels (capacity 5 mL) using a CEM Discover microwave reactor. HREIMS were recorded using a high-resolution magnetic trisector (EBE) mass analyser. The analytical thin-layer chromatography plates used were Polygram-Sil G/UV254. Preparative thin-layer chromatography was carried out with Analtech (Newark, NJ, USA) silica gel GF plates (20 × 20 cm, 1000 Microns) using appropriate mixtures of ethyl acetate and hexanes. All solvents and reagents were purified by standard techniques reported in \[[@B55-molecules-23-00199]\] or used as supplied from commercial sources. All compounds were named using the ACD40 Name-Pro program, which is based on IUPAC rules. Azides **7a**--**7m** were synthesized according to procedures previously described in the literature \[[@B47-molecules-23-00199],[@B48-molecules-23-00199],[@B49-molecules-23-00199],[@B50-molecules-23-00199],[@B56-molecules-23-00199]\].

*4-(Prop-2-yn-1-yloxy)-2H-chromen-2-one* (**3**). 259 µL (2.4 mmol) of propargyl bromide were slowly added to a mixture of 330.9 mg (2.0 mmol) of 4-hydroxycoumarin and 552.8 mg (4.0 mmol) of K~2~CO~3~ in 15 mL of acetone. The reaction mixture was refluxed for 8 h until disappearance of the starting coumarin. Then, the solvent was eliminated under reduced pressure, 30 mL of H~2~O were added and the mixture was extracted with AcOEt (3 × 30 mL). The organic phases were collected, washed with H~2~O (20 mL) and brine (20 mL) and dried over anhydrous MgSO~4~. After filtration and elimination of the solvent, the crude extract was purified by silica gel column chromatography using DCM as an eluent and 224.7mg (55%) of compound **3** were obtained as an amorphous white solid. Compound **3** showed identical spectroscopic data to those described in the literature \[[@B57-molecules-23-00199]\].

*4-(Prop-2-yn-1-ylamino)-2H-chromen-2-one* (**6**). 47 µL (0.72 mmol) of prop-2-yn-1-amine were slowly added to 200 mg (0.89 mmol) of 4-bromocoumarin in 2 mL of dimethylformamide (DMF) under argon atmosphere. The reaction mixture was stirred at room temperature for 18 h. Then water was added and the *N*-propargylated coumarin precipitated. After filtration, 111.8 mg (63%) of compound (**6**) was obtained as an amorphous white solid. m.p. 223--224 °C; ^1^H-NMR (600 MHz, (CDCl~3~) δ 7.57 (1H, t, *J* = 8.1 Hz), 7.46 (1H, d, *J* = 8.1 Hz), 7.37 (1H, d, *J* = 8.1 Hz), 7.30 (1H, t, *J* = 8.1 Hz), 5.46 (1H, s), 5.28 (1H, bs), 4.11 (2H, dd, *J* = 5.5, 2.5 Hz), 2.41 (1H, t, *J* = 2.5 Hz); ^13^C-NMR (150 MHz, (CDCl~3~) δ 162.5 (C=O), 153.6 (C), 151.8 (C), 132.0 (CH), 123.6 (CH), 119.9 (CH), 118.1 (CH), 113.9 (C), 85.9 (CH), 77.6 (C), 73.6 (CH~2~), 32.9(CH) ppm; EIMS *m*/*z* 199 (\[M^+^\], 71); 198 (61); 197 (13); 171 (100); 170 (53); 144 (13); 143 (22); 142 (27); 119 (12); 118 (16); 115 (15); 90 (11); 77 (18); 63 (14); 51 (14); HREIMS 199.0638 (calcd. for C~12~H~9~NO~2~ \[M^+^\] 199.0633); FT-IR (ATR) ν~max~ 3325, 3259, 3093, 3074, 2934, 2122, 1807, 1668, 1612, 1552, 1484, 1445, 1389, 1354, 1328, 1271, 1192, 1147, 1045, 983, 937, 865, 811 cm^−1^.

### 3.1.2. General Procedures for the Preparation of 4-Substituted 1,2,3-Triazole-Coumarin Derivatives {#sec3dot1dot2-molecules-23-00199}

*Method A.* Corresponding boronic acid (0.24 mmol) and 78.5 mg (1.2 mmol) of sodium azide in 1.5 mL of H~2~O were added to a vigorously stirred mixture of 3.4 mg (0.0241 mmol) of Cu~2~O in 0.06 mL of 20% of NH~3~ and 0.12 mL of H~2~O. The reaction mixture was stirred for 16 h at room temperature under an oxygen atmosphere. Then, 0.14 mmol of propargylated coumarin (**3** or **6**), 8.11 mg (0.041 mmol) of sodium ascorbate, 1.5 mL of H~2~O and 3 mL of acetone were added. The reaction was left at room temperature for 48h. Then, the reaction mixture was extracted with EtOAc. The aqueous phase was acidified with 5% HCl until pH = 2 and extracted with EtOAc (3 × 15 mL). The organic phases were collected, dried over anhydrous MgSO~4~ and after elimination of the solvent, the corresponding residue was purified by silica gel CC or TLC-preparative with DCM or 5% DCM/MeOH.

*Method B.* To a solution of 0.28 mmol of the corresponding azide in 3 mL of DCM, 0.14 mmol of propargylated coumarin (**3** or **6**), 3.6 mg (0.02 mmol) of sodium ascorbate, 1.2 mg (0.004 mmol) of CuSO~4~·5H~2~O and 3 mL of H~2~O, were added. The reaction mixture was stirred for 48 h at room temperature. The reaction mixture was extracted with EtOAc (3 × 15 mL). The organic phases were collected, dried over anhydrous MgSO~4~ and after elimination of the solvent, the corresponding residue was purified by silica gel CC or TLC-preparative with DCM or 5% DCM/MeOH.

*4-((1-Phenyl-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8a**). Following the experimental procedure described in method A, from 31.2 mg (0.24 mmol) of phenyl boronic acid and 28.0 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 10.9 mg (24%) of compound **8a** were obtained as an amorphous orange solid \[[@B58-molecules-23-00199]\]. m.p. 193--194 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 9.09 (1H,s), 7.95 (2H, d, *J* = 7.5 Hz), 7.83 (1H, dd, *J* = 7.9, 1.5 Hz), 7.65--7.63 (3H, m), 7.52 (1H, t, *J* = 7.4 Hz), 7.41 (1H, dd, *J* = 8.3, 0.7 Hz), 7.34 (1H, t, *J* = 7.6 Hz), 6.21 (1H, s), 5.53 (2H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 164.4 (C=O), 161.6 (C), 152.8 (C), 142.3 (C), 136.5 (C), 132.9 (CH), 129.9 (2CH), 128.9 (CH), 124.2 (CH), 123.4 (CH), 123.1 (CH), 120.3 (2CH), 116.5 (CH), 115.1 (C), 91.5 (CH), 62.8 (CH~2~) ppm; EIMS *m*/*z* 319 (\[M^+^\], 26); 131 (11); 130 (100); 103 (11); 77 (47); 51 (12); HREIMS319.0967 (calcd. for C~18~H~13~N~3~O~3~ \[M^+^\] 319.0957); FT-IR (ATR) ν~max~ 3386, 3146, 3097, 1716, 1621, 1563, 1494, 1460, 1397, 1367, 1337, 1243, 1208, 1186, 1136, 1100, 1029, 925, 835 cm^−1^.

*4-((1-(2-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8b**). Following the experimental procedure described in method B, from 42.3 mg (0.28 mmol) of 1-azido-2-methoxybenzene and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 14.2 mg (27%) of compound **8b** were obtained as an amorphous white solid. m.p. 200--201 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ 8.33 (1H, s), 7.84 (2H, dd, *J* = 7.9, 1.3 Hz), 7.56 (1H, t, *J* = 8.5 Hz), 7.47 (1H, t, *J* = 8.5 Hz), 7.32 (1H, dd, *J* = 8.3, 0.6 Hz), 7.25 (1H, td, *J* = 7.8, 1.1 Hz), 7.16--7.11 (2H, m), 5.93 (1H, s), 5.43 (2H, s), 3.93 (3H, s) ppm; ^13^C-NMR (125 MHz, CDCl~3~) δ 165.2 (C=O), 162.8 (C), 153.4 (C), 151.1 (C), 140.8 (C), 132.6 (CH), 130.6 (CH), 126.0 (C), 125.9 (CH), 125.5 (CH), 124.0 (CH), 123.4 (CH), 121.4 (CH), 116.8 (CH), 115.6 (C), 112.4 (CH), 91.2 (CH), 62.8 (CH~2~), 56.2 (CH~3~) ppm; EIMS *m*/*z* 349 (\[M^+^\], 37); 161 (12); 160 (100); 145 (28); 120 (14); 92 (11); 77 (16); HREIMS 349.1050 (calcd. for C~19~H~15~N~3~O~4~ \[M^+^\] 349.1063); FT-IR (ATR) ν~max~ 3400, 3129, 3093, 3009, 2942, 2841, 2287, 1707, 1617, 1563, 1507, 1493, 1477, 1460, 1410, 1368, 1233, 1186, 1136, 1103, 1052, 1018, 970, 930, 883, 868, 811 cm^−1^.

*4-((1-(3-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8c**). Following the experimental procedure described in method B, from 42.3 mg (0.28 mmol) of 1-azido-2-methoxybenzene and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 26.8 mg (51%) of compound **8c** were obtained as an amorphous white solid. m.p. 188--189 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ 8.16 (1H, s), 7.82 (1H, d, *J* = 7.6 Hz), 7.56 (1H, t, *J* = 7.4 Hz), 7.45 (1H, t, *J* = 8.1 Hz), 7.37 (1H, s), 7.33 (1H, d, *J* = 8.1 Hz), 7.30--7.21 (2H, m), 7.00 (1H, d, *J* = 7.8 Hz), 5.91 (1H, s), 5.43 (2H, s), 3.90 (3H, s) ppm;^13^C-NMR (125 MHz, CDCl~3~) δ 165.1 (C=O), 162.7 (C), 160.8 (C), 153.5 (C), 142.2 (C), 137.9 (C), 132.7 (CH), 130.8 (CH), 124.1 (CH), 123.3 (CH), 121.9 (CH), 116.9 (CH), 115.6 (C), 115.2 (CH), 112.7 (CH), 106.7 (CH), 91.4 (CH), 62.7 (CH~2~), 55.8 (CH~3~) ppm; EIMS *m*/*z* 349 (\[M^+^\], 49); 160 (100); 145 (18); 130 (16); 117 (12); 107 (14); 92 (18); 77 (21); HREIMS 349.1078 (calcd. for C~19~H~15~N~3~O~4~ \[M^+^\] 349.1063); FT-IR (ATR) ν~max~ 3401, 3148, 3093, 2933, 2838, 1719, 1620, 1610, 1565, 1493, 1456, 1400, 1368, 1337, 1237, 1189, 1158, 1103, 1044, 1004, 931, 833 cm^−1^.

*4-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8d**). Following the experimental procedure described in method B, from 42.3 mg (0.28 mmol) of 1-azido-4-methoxybenzene and 28.0 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 27.7 mg (53%) of compound **8d** were obtained as an amorphous white solid. m.p. 195--196 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ 8.07 (1H, s), 7.83 (1H, d, *J* = 8.0 Hz), 7.66 (2H, d, *J* = 8.9 Hz), 7.56 (1H, t, *J* = 7.8 Hz), 7.33 (1H, d, *J* = 8.3 Hz), 7.4 (1H, t, *J* = 7.9 Hz), 7.05 (2H, d, *J* = 8.9 Hz), 5.91 (1H, s), 5.42 (2H, s), 3.89 (3H, s) ppm; ^13^C-NMR (125 MHz, CDCl~3~) δ 165.1 (C=O), 162.7 (C), 160.3 (C), 153.5 (C), 142.1 (C), 132.7 (CH), 130.3 (C), 124.1 (CH), 123.3 (CH), 122.5 (2CH), 121.9 (CH), 116.9 (CH), 115.6 (C), 115.0 (2CH), 91.4 (CH), 62.8 (CH~2~), 55.8 (CH~3~) ppm; EIMS *m*/*z* 349 (\[M^+^\], 29); 161 (12); 160 (100); 145 (13); 92 (12); 77 (13); HREIMS 349.1061 (calcd. for C~19~H~15~N~3~O~4~ \[M^+^\] 349.1063); FT-IR (ATR) ν~max~ 3140, 3095, 3006, 2942, 2840, 2381, 2055, 1719, 1619, 1564, 1519, 1457, 1400, 1369, 1257, 1240, 1185, 1137, 1102, 1030, 927, 824 cm^−1^.

*4-((1-(3-Fluoro-4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8e**). Following the experimental procedure described in method B, from 47.4 mg (0.28 mmol) of 1-azido-3-fluoro-4-methoxybenzene and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 25.3 mg (46%) of compound **8e** were obtained as an amorphous white solid. m.p. 190--191 °C; ^1^H-NMR (600 MHz, CDCl~3~) δ 8.07 (1H, s), 7.82 (1H, dd, *J* = 8.0, 1.0 Hz), 7.60--7.51 (2H, m), 7.48 (1H, d, *J* = 8.8 Hz), 7.33 (1H, d, *J* = 8.3 Hz), 7.24 (1H, t, *J* = 7.9 Hz), 7.11 (1H, t, *J* = 8.7 Hz), 5.91 (1H, s), 5.42 (2H, s), 3.97 (3H, s) ppm; ^13^C-NMR (150 MHz, CDCl~3~) δ 165.1 (C=O), 162.7 (C), 153.4 (C), 152.3 (*J*^1^~C--F~ = 249.1 Hz), 148.6 (C, *J*^2^~C--F~ = 28.7 Hz), 142.4 (C), 132.8 (CH), 124.1 (CH), 123.3 (CH), 121.8 (CH), 117.0 (CH), 116.8 (CH, *J*^3^~C--F~ = 3.6 Hz), 115.6 (C), 114.0 (CH, *J*^3^~C--F~ = 1.9 Hz), 110.0 (CH, *J*^2^~C--F~ = 22.6 Hz), 91.5 (CH), 62.7 (CH~2~), 56.7 (CH~3~) ppm; EIMS *m*/*z* 367 (\[M^+^\], 27); 179 (12); 178 (100); 163 (21); HREIMS367.0898 (calcd. for C~19~H~14~N~3~O~4~F \[M^+^\] 367.0968); FT-IR (ATR) ν~max~ 3488, 3143, 3089, 2976, 2944, 2844, 2361, 1715, 1620, 1565, 1527, 1493, 1451, 1401, 1368, 1328, 1287, 1243, 1233, 1186, 1159, 1133, 1104, 1017, 952, 933, 880, 833, 808 cm^−1^.

*4-((1-(4-Fluoro-phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8f**). Following the experimental procedure described in method A, from 34.8 mg (0.24 mmol) of 4-fluorophenyl boronic acid and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 22.1 mg (43%) of compound **8f** were obtained as an amorphous white solid. m.p. 233--235 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 9.07 (1H, s), 8.02--7.98 (2H, m), 7.83 (1H, dd, *J =* 7.9, 1.5 Hz), 7.67 (1H, ddd, *J =* 8.7, 7.4, 1.6 Hz), 7.49 (2H, t, *J =* 8.8 Hz), 7.42 (1H, dd, *J =* 8.3, 0.6 Hz), 7.35 (1H, t, *J =* 7.6 Hz), 6.20 (1H, s), 5.52 (2H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 164.3 (C=O), 161.5 (C), 161.4 (C, *J*^1^~C--F~ = 245.7 Hz), 152.7 (C), 142.3 (C), 133.0 (C, *J*^4^~C--F~ = 3.4 Hz), 132.9 (CH), 124.2 (CH), 123.6 (CH), 123.0 (CH), 122.7 (2 CH, *J*^3^~C--F~ = 8.6 Hz), 116.8 (2 CH, *J*^2^~C--F~ = 24.1 Hz), 116.5 (CH), 115.1 (C), 91.5 (CH), 62.8 (CH~2~); EIMS *m*/*z* 337 (\[M^+^\], 23); 149 (11); 148 (100); 95 (25); HREIMS 337.0859 (calcd. for C~18~H~12~N~3~O~3~F \[M^+^\] 337.0863). FT-IR (ATR) ν~max~ 3148, 3098, 2384, 2294, 2050, 1718, 1624, 1567, 1516, 1496, 1465, 1454, 1401, 1370, 1233, 1184, 1105, 1051, 1022, 951, 931, 833 cm^−1^.

*4-((1-(3-Trifluoromethyl-phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8g**). Following the experimental procedure described in method B, from 53.2 mg (0.28 mmol) of 1-azido-3-trifluoromethylbenzene and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 24.0 mg (41%) of compound **8g** were obtained as an amorphous white solid. m.p. 192--193 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 9.27 (1H, s), 8.34 (1H, s), 8.32 (1H, d, *J* = 8.2 Hz), 7.93--7.86 (2H, m), 7.85 (1H, dd, *J* = 8.0, 1.5 Hz), 7.68 (1H, ddd, *J* = 8.8, 7.4, 1.6 Hz), 7.43 (1H, d, *J* = 7.7 Hz), 7.37 (1H, t, *J* = 7.6 Hz), 6.22 (1H, s), 5.56 (2H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 164.3 (C=O), 165.1 (C), 152.7 (C), 142.5 (C), 136.9 (C), 132.8 (CH), 131.3 (CH), 130.5 (C, *J*^2^~C--F~ = 29.6 Hz), 125.4 (CH, *J*^3^~C--F~ = 4.1 Hz), 124.2 (CH), 124.1 (CH), 123.5 (C, *J*^1^~C--F~ = 276.4 Hz), 123.7 (CH), 123.0 (CH), 116.9 (CH, *J*^3^~C--F~ = 4.5 Hz), 116.4 (CH), 115.0 (C), 91.5 (CH), 62.7 (CH~2~);EIMS *m*/*z* 387 (\[M^+^\], 12); 386 (42); 358 (23); 357 (45); 329 (10); 199 (12); 198 (100); 159 (26); 145 (50); HREIMS 387.0846 (calcd. for C~19~H~12~N~3~O~3~F~3~ \[M^+^\] 387.0831); FT-IR (ATR) ν~max~ 3531, 3409, 1685, 1618, 1559, 1069, 972 cm^--1^.

*4-((1-(3-Nitro-phenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8h**). Following the experimental procedure described in method B, from 46.6 mg (0.28 mmol) of 1-azido-3-nitrobenzene and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 23.1 mg (43%) of compound **8g** were obtained as an amorphous white solid. m.p. 215--217 °C; ^1^H-NMR (600 MHz, (CD~3~)~2~SO) δ 9.31 (1H, s), 8.78 (1H, s), 8.45 (1H, d, *J* = 7.8 Hz), 8.36 (1H, d, *J* = 7.9 Hz), 7.93 (1H, t, *J* = 8.1 Hz), 7.85 (1H, d, *J* = 7.8 Hz), 7.67 (1H, t, *J* = 7.6 Hz), 7.42 (1H, d, *J* = 8.3 Hz), 7.36 (1H, t, *J* = 7.5 Hz), 6.21 (1H, s), 5.56 (2H, s) ppm; ^13^C-NMR (150 MHz, (CD~3~)~2~SO) δ 164.4 (C=O), 161.6 (C), 152.8 (C), 148.6 (C), 142.8 (C), 137.1 (C), 133.0 (CH), 131.7 (CH), 126.4 (CH), 124.3 (CH), 123.9 (CH), 123.4 (CH), 123.1 (CH), 116.5 (CH), 115.2 (CH), 115.1 (C), 91.6 (CH), 62.8 (CH~2~) ppm; EIMS *m*/*z* 364 (\[M^+^\], 59); 176 (11); 175 (100); 162 (23); 145 (14); 129 (92); 128 (37); 121 (14); 120 (39); 92 (18); 77 (11); 76 (37); HREIMS 364.0820 (calcd. for C~18~H~12~N~4~O~5~ \[M^+^\] 364.0808); FT-IR (ATR) ν~max~ 3431, 3146, 3091, 2925, 1713, 1617, 1565, 1531, 1493, 1464, 1406, 1352, 1245, 1185, 1138, 1104, 1045, 1009, 980, 952, 929, 830 cm^--1^.

*4-((1-(1H-Indole-5-yl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8i**). Following the experimental procedure described in method B, from 44.9 mg (0.28 mmol) of 5-azido-1*H*-indol and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 18.1 mg (33%) of compound **8i** were obtained as an amorphous white solid. m.p. 191--193 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 11.46 (1H, s), 8.99 (1H, s), 8.05 (1H, s), 7.84 (1H, d, *J* = 7.1 Hz), 7.67 (1H, t, *J* = 7.2 Hz), 7.63--7.57 (2H, m), 7.53--7.51 (1H, m), 7.42 (1H, d, *J* = 8.3 Hz), 7.35 (1H, t, *J* = 7.5 Hz), 6.59 (1H, s), 6.22 (1H, s), 5.52 (2H, s); ^13^C NMR (125 MHz, (CD~3~)~2~SO) 164.4 (C=O), 161.6 (C), 152.8 (C), 141.8 (C), 135.6 (C), 132.9 (CH), 129.3 (C), 127.8 (CH), 127.6 (C), 124.3 (CH), 123.7 (CH), 123.1 (CH), 116.5 (CH), 115.1 (C), 114.4 (CH), 112.4 (CH), 112.3 (CH), 102.0 (CH), 91.4 (CH), 62.9 (CH~2~) ppm; EIMS *m*/*z* 358 (\[M^+^\], 28); 169 (100); 168 (19); 162 (30); 121 (13); 120 (39); 116 (28); 92 (14); HREIMS 358.1068 (calcd. for C~20~H~14~N~4~O~3~ \[M^+^\] 358.1066); FT-IR (ATR) ν~max~ 3399, 3299, 1699, 1685, 1616, 1563, 1494, 1403, 1350, 1327, 1228, 1097, 1048, 1025, 993 cm^--1^.

*4-((1-(Furan-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8j**). Following the experimental procedure described in method A, from 34.8 mg (0.24mmol) of 3-furylboronic acid and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 8.1 mg (18%) of compound **8j** were obtained as an amorphous white solid. m.p. 189--190 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.88 (1H,s), 8.48 (1H, s), 7.91 (1H, t, *J* = 1.9 Hz), 7.80 (1H, dd, *J* = 7.9, 1.5 Hz), 7.67 (1H, t, *J* = 7.6Hz), 7.42 (1H, dd, *J* = 8.3, 0.7 Hz), 7.35 (1H, t, *J* = 7.8 Hz), 7.16 (1H, dd, *J* = 2.0, 0.9 Hz), 6.19 (1H, s), 5.51 (2H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 164.4 (C=O), 161.6 (C), 152.8 (C), 144.9 (CH), 141.9 (C), 134.3 (CH), 132.9 (CH), 125.9 (C), 124.3 (CH), 124.2 (CH), 123.0 (CH), 116.5 (CH), 115.1 (C), 105.3 (CH), 91.5 (CH), 62.7 (CH~2~) ppm; EIMS *m*/*z* 309 (\[M^+^\], 59); 279 (25); 198 (21); 159 (23); 120 (100); 94 (18); 65 (13); HREIMS 309.0662 (calcd. for C~16~H~11~N~3~O~4~ \[M^+^\] 309.0671). FT-IR (ATR) ν~max~ 3514, 3399, 3084, 2924, 2387, 2094, 2064, 1992, 1696, 1619, 1606, 1563, 1492, 1450, 1410, 1365, 1270, 1248, 1193, 1105, 1053, 1023, 942, 911, 871, 839 cm^−1^.

*4-((1-Undecyl-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8k**). Following the experimental procedure described in method B, from 56.1 mg (0.28mmol) of 1-azido-undecane and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 51.4 mg (86%) of compound **8k** were obtained as an amorphous white solid. m.p. 144--145 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ 7.78 (1H, dd, *J* = 13.2, 6.5 Hz), 7.75 (1H, s), 7.54 (1H, t, *J* = 7.5 Hz), 7.30 (1H, d, *J* = 7.9 Hz), 7.24 (1H, t, *J* = 7.6 Hz), 5.87 (1H, s), 5.34 (1H, s), 4.41 (2H, t, *J* = 7.3 Hz), 1.96 (2H, t, *J* = 7.2 Hz), 1.38--1.23 (16H, m), 0.87 (3H, t, *J* = 6.9 Hz) ppm; ^13^C-NMR (125 MHz, CDCl~3~) δ 165.1 (C=O), 162.7 (C), 153.4 (C), 141.4 (C), 132.6 (CH), 124.0 (CH), 123.4 (CH), 123.2 (CH), 116.8 (CH), 115.5 (C), 91.2 (CH), 62.8 (CH~2~), 50.7 (CH~2~), 31.9 (CH~2~), 30.3 (CH~2~), 29.6 (CH~2~), 29.5 (CH~2~), 29.4 (CH~2~), 29.3 (CH~2~), 29.0 (CH~2~), 26.6 (CH~2~), 22.7 (CH~2~), 14.2 (CH~3~) ppm; EIMS *m*/*z* 397 (\[M^+^\], 18); 236 (17); 209 (15); 208 (100); 68 (21); 57 (16); 55 (15); HREIMS 397.2351 (calcd. for C~23~H~31~N~3~O~3~ \[M^+^\] 397.2365); FT-IR (ATR) ν~max~ 3134, 3075, 2918, 2849, 1725, 1623, 1610, 1566, 1492, 1458, 1424, 1381, 1328, 1272, 1248, 1187, 1154, 1138, 1106, 1059, 1031, 979, 931, 882, 851, 814 cm^−1^.

*4-((1-Benzyl-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8l**). Following the experimental procedure described in method B, from 40.8 mg (0.28 mmol) of benzylazide and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 47.0 mg (94%) of compound **8l** were obtained as an amorphous white solid. m.p. 210--211 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ 7.76 (1H, dd, *J* = 7.9, 1.5 Hz), 7.63 (1H, s), 7.56--7.52 (1H, t, *J* = 7.6 Hz), 7.47--7.36 (3H, m), 7.35--7.28 (3H, m), 7.23 (1H, t, *J* = 7.6 Hz), 5.84 (s, 1H), 5.59 (s, 2H), 5.31 (2H, d, *J* = 3.8 Hz) ppm; ^13^C-NMR (125 MHz, CDCl~3~) δ 165.1 (C=O), 162.5 (C), 153.7 (C), 142.1 (C), 134.4 (C), 132.6 (CH), 129.5 (2CH), 129.2 (CH), 128.4 (2CH), 124.0 (CH), 123.3 (CH), 123.2 (CH), 117.0 (CH), 115.8 (C), 91.5 (CH), 62.9 (CH~2~), 54.6 (CH~2~) ppm; EIMS *m*/*z* 333 (\[M^+^\], 39); 172 (13); 144 (62); 104 (11); 92 (14); 91 (100); HREIMS 333.1116 (calcd. for C~19~H~15~N~3~O~3~\[M^+^\] 333.1113); FT-IR (ATR) ν~max~ 3075, 1722, 1625, 1569, 1498, 1459, 1421, 1377, 1331, 1277, 1250, 1187, 1141, 1111, 1063, 1035, 983, 933, 885, 849, 814 cm^−1^.

*4-((1-Tetradecyl-1H-1,2,3-triazol-4-yl)methoxy)-2H-chromen-2-one* (**8m**). Following the experimental procedure described in method B, from 68.0 mg (0.28 mmol) of 1-azido-tetradecane and 28 mg (0.14 mmol) of *O*-propargylated coumarin (**3**), 61.3 mg (93%) of compound **8m** were obtained as an amorphous white solid. m.p. 146--147 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ 7.79 (1H, dt, *J* = 7.9, 1.5 Hz), 7.72 (1H, s), 7.54 (1H, tt, *J* = 9.1, 1.7 Hz), 7.31 (1H, dd, *J* = 8.4, 1.5 Hz), 7.24 (1H, t, *J* = 7.6 Hz), 5.87 (1H, s), 5.35 (2H, s), 4.41 (2H, t, *J* = 7.3 Hz), 1.96 (2H, t, *J* = 7.1 Hz), 1.38--1.23 (22H, m), 0.88 (3H, t, *J* = 6.9 Hz) ppm; ^13^C-NMR (125 MHz, CDCl~3~) δ 165.1 (C=O), 162.8 (C), 153.4 (C), 141.4 (C), 132.6 (CH), 124.0 (CH), 123.4 (CH), 123.3 (CH), 116.8 (CH), 115.6 (C), 91.2 (CH), 62.8 (CH~2~), 50.8 (CH~2~), 32.0 (CH~2~), 31.0 (CH), 30.4 (CH~2~), 29.9 (CH~2~), 29.8 (CH~2~), 29.7 (2CH~2~), 29.6 (CH~2~), 29.5 (CH~2~), 29.4 (CH~2~), 29.1 (CH~2~), 26.6 (CH~2~), 22.8 (CH~2~), 14.2 (CH~3~) ppm; EIMS *m*/*z* 439 (\[M^+^\], 11); 278 (26); 251 (19); 250 (100); 215 (20); 120 (10); 71 (14); 70 (12); 68 (23); 57 (22); 56 (10); 55 (19); HREIMS 439.2852 (calcd. for C~26~H~37~N~3~O~3~ \[M^+^\] 439.2835); FT-IR (ATR) ν~max~ 3135, 3075, 2918, 2849, 1817, 1726, 1624, 1567, 1468, 1423, 1381, 1328, 1273, 1248, 1185, 1154, 1139, 1107, 1058, 979, 931, 882, 851, 814 cm^−1^.

*4-(((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9a**). Following the experimental procedure described in method A, from 31.2 mg (0.24 mmol) of phenyl boronic acid and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 13.8 mg (28%) of compound **9a** were obtained as an amorphous white solid. m.p. 194--195 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.82 (1H, s), 8.31 (1H, t, *J* = 5.6 Hz), 8.10 (1H, dd, *J* = 8.0, 1.0 Hz), 7.90 (2H, d, *J* = 7.6 Hz), 7.61--7.56 (3H, m), 7.48 (1H, t, *J* = 7.4 Hz), 7.36--7.30 (2H, m), 5.30 (1H, s), 4.64 (2H, d, *J* = 5.6 Hz) ppm; ^13^C-NMR (125 MHz,(CD~3~)~2~SO) δ 161.5 (C=O), 153.1 (C),153.0 (C), 144.6 (C), 136.6 (C), 132.0 (CH), 130.0 (CH), 128.7 (CH), 123.4 (CH), 122.6 (CH), 121.5 (CH), 120.0 (CH), 117.0 (CH), 114.5 (C), 82.5 (CH), 37.8 (CH~2~) ppm; EIMS *m*/*z* 318(\[M^+^\], 64); 290 (21); 289 (44); 261 (16); 198 (15); 159 (22); 130 (100); 77 (56); HREIMS 318.1117 (calcd. for C~18~H~14~N~4~O~2~ \[M^+^\] 318.1117); FT-IR (ATR) ν~max~ 3500, 3297, 3138, 3082, 2940, 1707, 1609, 1557, 1503, 1480, 1146, 1377, 1340, 1321, 1188, 1054, 954, 922, 861, 823 cm^−1^.

*4-(((1-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9b**). Following the experimental procedure described in method B, from 68.0 mg (0.28 mmol) of 1-azido-2-methoxybenzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 16.9 mg (32%) of compound **9b** were obtained as an amorphous white solid. m.p. 187--189 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.36 (1H, s), 8.09 (1H, t, *J* = 5.5 Hz), 8.01 (1H, dd, *J* = 8.1, 1.2 Hz), 7.54 (1H, dd, *J* = 7.9, 1.6 Hz), 7.51 (1H, dd, *J* = 11.3, 4.2 Hz), 7.44 (1H, t, *J* = 7.9 Hz), 7.27--7.20 (m, 3H), 7.06 (1H, td, *J* = 7.7, 1.0 Hz, ), 5.30 (1H, s), 4.56 (2H, d, *J* = 5.7 Hz), 3.77 (3H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.2 (C=O), 153.0 (C), 152.8 (C), 151.4 (C), 142.9 (C), 131.7 (CH), 130.4 (CH), 125.7 (C), 125.4 (CH), 125.1 (CH), 123.1 (CH), 122.4 (CH), 120.8 (CH), 116.7 (CH), 114.4 (C), 113.0 (CH), 82.5 (CH), 56.0 (CH~3~), 37.5 (CH~2~) ppm; EIMS *m*/*z* 348 (\[M^+^\], 20); 320 (17); 319 (20); 160 (100); 159 (20); 145 (11); 120 (11); 77 (19); HREIMS 348.1228 (calcd. for C~19~H~16~N~4~O~3~ \[M^+^\] 348.1222); FT-IR (ATR) ν~max~ 3524, 3318, 3173, 3085, 2944, 2847, 2376, 1649, 1607, 1555, 1505, 1476, 1446, 1384, 1327, 1290, 1260, 1244, 1197, 1120, 1044, 1017, 957, 937, 865 cm^−1^.

*4-(((1-(3-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9c**). Following the experimental procedure described in method B, from 42.3 mg (0.28 mmol) of 1-azido-3-methoxybenzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 26.9 mg (51%) of compound **9c** were obtained as an amorphous white solid. m.p. 246--248 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.71 (1H, s), 8.08 (1H, t, *J* = 5.5 Hz), 8.02 (1H, dd, *J* = 8.1, 1.2 Hz), 7.52 (1H, t, *J* = 7.8 Hz), 7.44--7.36 (3H, m), 7.27 (1H, d, *J* = 0.8 Hz), 7.24 (1H, t, *J* = 7.7 Hz), 6.97 (1H, dt, *J* = 6.8, 2.5 Hz), 5.25 (1H, s), 4.57 (2H, d, *J* = 5.6 Hz), 3.78 (3H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.2 (C=O), 160.1 (C), 153.0 (C), 152.7 (C), 144.3 (C), 137.5 (C), 131.7 (CH), 130.6 (CH), 123.1 (CH), 123.0 (CH), 121.5 (CH), 116.7 (CH), 114.4 (C), 114.2 (CH), 111.9 (CH), 105.7 (CH), 82.5 (CH), 55.5 (CH~3~), 37.7 (CH~2~) ppm; EIMS *m*/*z* 348 (\[M^+^\], 40); 319 (25); 291 (10); 198 (11); 161 (13); 160 (100); 159 (30); 123 (11); 107 (24); 92 (19); 77 (26); HREIMS 348.1221 (calcd. for C~19~H~16~N~4~O~3~ \[M^+^\] 348.1222); FT-IR (ATR) ν~max~ 3297, 3143, 3085, 3000, 2936, 2830, 1708, 1609, 1558, 1483, 1446, 1373, 1322, 1246, 1192, 1158, 1142, 1118, 1048, 954, 922, 859, 846, 819 cm^−1^.

*4-(((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9d**). Following the experimental procedure described in method B, from 42.3 mg (0.28 mmol) of 1-azido-4-methoxybenzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 29.6 mg (56%) of compound **9d** were obtained as an amorphous white solid. m.p. 246--248 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.58 (1H, s), 8.07 (1H, t, *J* = 5.4 Hz), 8.01 (1H, dd, *J* = 8.1, 1.1 Hz), 7.74--7.69 (2H, m), 7.52 (1H, t, *J* = 7.8 Hz), 7.24 (2H, dd, *J* = 14.4, 7.6 Hz), 7.07--7.01 (2H, m), 5.25 (1H, s), 4.55 (2H, d, *J* = 5.6 Hz), 3.75 (3H, s) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.2 (C=O), 159.2 (C), 153.0 (C), 152.8 (C), 144.1 (C), 131.7 (CH), 130.0 (C), 123.1 (CH), 122.4 (CH), 121.6 (2CH), 121.3 (CH), 116.7 (CH), 114.7 (2CH), 114.4 (C), 82.5 (CH), 55.4 (CH~3~), 37.7 (CH~2~) ppm; EIMS *m*/*z* 348 (\[M^+^\], 21); 320 (14); 319 (22); 161 (12); 160 (100); 159 (26); 123 (10); 77 (15); HREIMS 348.1225 (calcd. for C~19~H~16~N~4~O~3~ \[M^+^\] 348.1222); FT-IR (ATR) ν~max~ 3528, 3285, 3137, 3081, 3067, 3003, 2945, 2924, 2829, 2310, 2051, 1700, 1609, 1556, 1517, 1446, 1378, 1307, 1247, 1187, 1140, 1055, 1041, 989, 953, 920, 860, 822 cm^−1^.

*4-(((1-(3-Fluoro-4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9e**). Following the experimental procedure described in method B, from 47.4 mg (0.28 mmol) of 1-azido-3-fluoro-4-methoxybenzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 27.3 mg (49 %) of compound **9e** were obtained as an amorphous white solid. m.p. 204--205 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.76 (1H, s), 8.29 (1H, t, *J* = 5.7 Hz), 8.09 (1H, dd, *J* = 8.1, 1.2 Hz), 7.87 (1H, dd, *J* = 12.1, 2.6 Hz), 7.72 (1H, ddd, *J* = 8.9, 2.5, 1.4 Hz), 7.60 (1H, t, *J* = 7.8 Hz), 7.39--7.30 (3H, m), 5.28 (1H, s), 4.62 (2H, d, *J* = 5.6 Hz), 3.90 (3H, s); ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 162.4 (C=O), 153.7 (C), 153.4 (C), 151.6 (C, *J*^1^~C--F~ = 247.8 Hz), 147.7 (C, *J*^2^~C--F~ = 20.3 Hz), 144.9 (C), 132.7 (CH), 129.9 (C, *J*^3^~C--F~ = 9.0 Hz), 124.1 (CH), 122.8 (CH), 122.1 (CH), 117.4 (CH), 117.0 (CH,*J*^3^~C--F~ = 2.8 Hz), 114.9 (C), 114.7 (CH), 109.2 (CH, *J*^2^~C--F~ = 22.5 Hz), 82.8 (CH), 56.7 (CH~3~), 38.0 (CH~2~) ppm; EIMS *m*/*z* 366 (\[M^+^\], 30); 338 (16); 337 (22); 198 (15); 179 (13); 178 (100); 159 (22); HREIMS 366.1138 (calcd. for C~19~H~15~N~4~O~3~F \[M^+^\] 366.1128); FT-IR (ATR) ν~max~ 3301, 3133, 3078, 3009, 2936, 2849, 1699, 1609, 1557, 1518, 1477, 1446, 1377, 1317, 1184, 1123, 1082, 1053, 953, 921, 884, 859, 817 cm^−1^.

*4-(((1-(4-Fluoro-phenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9f**). Following the experimental procedure described in method A, from 34.8 mg (0.24mmol) of 4-fluoro-phenyl boronic acid and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 15.2 mg (30 %) of compound **9f** were obtained as an amorphous white solid. m.p. 212--213 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.79 (1H, s), 8.32 (1H, t, *J =* 6.0 Hz), 8.16 (1H, d, *J =* 7.8 Hz), 7.97--7.91 (2H, m), 7.61 (1H, t, *J =* 8.4 Hz), 7.45 (2H, t, *J =* 8.8 Hz), 7.35--7.30 (2H, m), 5.30 (1H, s), 4.6 (2H, d, *J =* 5.5 Hz) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.4 (C=O), 153.1 (C), 153.0 (C), 144.7 (C), 133.1 (C), 132.0 (CH), 123.4 (CH), 122.6 (CH), 122.3 (2CH, *J*^3^~C--F~ = 9.1 Hz), 121.7 (C), 116.9 (CH), 116.7 (2CH, *J*^2^~C--F~ = 23.9 Hz), 114.5 (C), 82.6 (CH), 37.4 (CH~2~) ppm; EIMS *m*/*z* 336 (\[M^+^\], 54); 308 (19); 307 (36); 198 (15); 159 (27); 148 (100); 95 (38); HREIMS 336.1030 (calcd. for C~18~H~13~N~4~O~2~F \[M^+^\] 336.1023); FT-IR (ATR) ν~max~ 3537, 3417, 3307, 3143, 3084, 2454, 2288, 2167, 2051, 1985, 1707, 1610, 1558, 1541, 1516, 1481, 1447, 1377, 1230, 1183, 1051, 993, 957, 920, 825 cm^−1^.

*4-(((1-(3-Trifluoromethylphenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9g**). Following the experimental procedure described in method B, from 53.2 mg (0.28 mmol) of 1-azido-3-trifluoromethylbenzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 26.2 mg (45 %) of compound **9g** were obtained as an amorphous white solid. m.p. 231--232 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 9.00 (1H, s), 8.32 (1H, t, *J* = 5.7 Hz), 8.29--8.24 (2H, m), 8.09 (1H, dd, *J* = 8.1, 1.2 Hz), 7.88--7.80 (2H, m), 7.60 (1H, dd, *J* = 15.6, 1.4 Hz), 7.34 (2H, ddd, *J* = 9.2, 8.2, 1.0 Hz), 5.29 (1H, s), 4.66 (2H, d, *J* = 5.7 Hz) ppm; ^13^C-NMR (125MHz, (CD~3~)~2~SO) δ 161.5 (C=O), 153.1 (C), 153.0 (C), 145.0 (C), 137.1 (C), 132.0 (CH), 131.4 (CH), 130.5 (C, *J*^2^~C--F~ = 32.5 Hz), 125.2(CH, *J*^3^~C--F~ = 3.1 Hz), 123.9 (CH), 123.6 (C, *J*^1^~C--F~ = 272.5 Hz), 123.4 (CH), 122.6 (CH), 121.8 (CH), 117.0 (CH), 116.7 (CH, *J*^3^~C-F~= 3.8 Hz), 114.5 (C), 82.6 (CH), 37.8 (CH~2~); EM-IE *m*/*z* 386 (\[M^+^\], 72); 358 (26); 357 (50); 198 (100); 159 (29); 145 (49); HREIMS 386.0977 (calcd. for C~19~H~13~N~4~O~2~F~3~ \[M^+^\] 386.0991); FT-IR (ATR) ν~max~ 3425, 3318, 3142, 3085, 2942, 1701, 1610, 1557, 1540, 1482, 1448, 1377, 1342, 1321, 1298, 1266, 1248, 1172, 1142, 1110, 1070, 1046, 955, 923, 896, 861, 819 cm^--1^.

*4-(((1-(3-Nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9h**). Following the experimental procedure described in method B, from 46.6 mg (0.28 mmol) of 1-azido-3-nitrobenzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 21.2 mg (39 %) of compound **9h** were obtained as an amorphous white solid. m.p. 240--241 °C; ^1^H-NMR (600 MHz, (CD~3~)~2~SO) δ 9.06 (1H, s), 8.73 (1H, t, *J* = 1.9 Hz), 8.42 (1H, d, *J* = 7.8 Hz), 8.32 (2H, dd, *J* = 8.2, 2.1 Hz), 8.10 (1H, d, *J* = 7.9 Hz), 7.93--7.83 (1H, m), 7.61 (1H, t, *J* = 7.4 Hz), 7.37--7.27 (2H, m), 5.29 (1H, s), 4.67 (2H, d, *J* = 5.4 Hz) ppm; ^13^C-NMR (150 MHz, (CD~3~)~2~SO) δ 161.4 (C=O), 153.1 (C), 153.0 (C), 148.6 (C), 145.2 (C), 137.1 (C), 132.0 (CH), 131.5 (CH), 126.0 (CH), 123.4 (CH), 123.1 (CH), 122.5 (CH), 122.0 (CH), 116.9 (CH), 114.7 (CH), 114.5 (C), 82.61 (CH), 37.7 (CH~2~) ppm; EIMS *m*/*z* 363 (\[M^+^\], 48); 335 (31); 334 (69); 333 (100); 286 (23); 242 (30); 198 (28); 197 (31); 175 (40); 161 (38); 159 (31); 129 (40); 92 (27); 76 (30); 65 (27); HREIMS 363.0983 (calcd. for C~18~H~13~N~5~O~4~ \[M^+^\] 363.0968); FT-IR (ATR) ν~max~ 3426, 3137, 3106, 3082, 2927, 1707, 1614, 1561, 1531, 1481, 1448, 1352, 1315, 1269, 1189, 1142, 1119, 1043, 1001, 960, 925, 863, 818 cm^−1^.

*4-(((1-(1H-Indole-5-yl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9i**). Following the experimental procedure described in method B, from 44.9 mg (0.28 mmol) of 5-azido-1*H*-indole and 28.0 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 20.7 mg (37 %) of compound **9i** were obtained as an amorphous white solid. m.p. 236--237 °C;^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 11.42 (1H, bs), 8.72 (1H, s), 8.29 (1H, t, *J* = 5.6 Hz), 8.11 (1H, d, *J* = 7.2 Hz), 8.00 (1H, s), 7.63--7.53 (3H, m), 7.50 (1H, s), 7.33 (2H, dd, *J* = 12.4, 7.8 Hz), 6.55 (1H, s, *J* = 2.1 Hz), 5.34 (1H, s), 4.63 (2H, d, *J* = 5.6 Hz) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO)δ162.4 (C=O), 161.5 (C), 153.1 (C), 153.0(C), 144.1 (C), 135.5 (C), 132.0 (CH), 129.5 (C), 127.7 (CH), 127.6 (C), 123.4 (CH), 122.6 (CH), 121.9 (CH), 116.9 (CH), 114.5 (C), 114.2 (CH), 112.3 (CH), 111.9 (CH), 101.9 (CH), 82.5 (CH), 37.9 (CH~2~); EIMS *m*/*z* 357 (\[M^+^\], 27); 329 (14); 328 (23); 170 (16); 169 (100); 168 (30); 156 (23); 132 (21); 116 (57); 115 (16); 89 (19); HREIMS 357.1217 (calcd. for C~20~H~15~N~5~O~2~ \[M^+^\] 357.1226); FT-IR (ATR) ν~max~ 3522, 3397, 3324, 1682, 1616, 1562, 1486, 1354, 1092, 1053, 886 cm^−1^.

*4-(((1-(Furan-3-yl)-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9j**). Following the experimental procedure described in method A, from 21.3 mg (0.24 mmol) of 3-furyl boronic acid and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 5.4 mg (12%) of compound **9j** were obtained as an amorphous white solid. m.p. 198--199 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.58 (1H, s), 8.42 (1H, d, *J* = 0.8 Hz), 8.30 (1H, t, *J* = 5.6 Hz), 8.08 (1H, d, *J* = 6.9 Hz), 7.86 (1H, t, *J* = 1.8 Hz), 7.60 (1H, t, *J* = 7.8 Hz), 7.32 (2H, dd, *J* = 8.1, 4.6 Hz), 7.12 (1H, dd, *J* = 2.0, 0.8 Hz), 5.27 (1H, s), 4.62 (2H, d, *J* = 5.6 Hz) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.4 (C=O), 153.1 (C), 153.0 (C), 144.8 (CH), 144.3 (C), 133.9 (CH), 132.0 (CH), 126.0 (C), 123.4 (CH), 122.6 (CH), 122.2 (CH), 117.0 (CH), 114.5 (C), 105.1 (CH), 82.5 (CH), 37.7 (CH~2~) ppm; EIMS *m*/*z* 308 (\[M^+^\], 99); 120 (67); 93 (28); 91 (12); 66 (23); 65 (100); 58 (17); HREIMS 308.1000 (calcd. for C~16~H~12~N~4~O~3~ \[M^+^\] 308.0988); FT-IR (ATR) ν~max~ 3293, 3134, 3083, 2924, 2853, 2285, 1706, 1610, 1557, 1480, 1446, 1378, 1323, 1262, 1230, 1191, 1143, 1118, 1089, 1039, 1017, 955, 921, 867, 821 cm^−1^.

*4-(((1-Undecyl-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9k**). Following the experimental procedure described in method B, from 56.1 mg (0.28 mmol) of 1-azido-undecane and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 50.3 mg (84%) of compound **9k** were obtained as an amorphous white solid. m.p. 154--156 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.08--7.93 (3H, m), 7.51 (1H, t, *J* = 7.7 Hz), 7.25 (1H, s), 7.22 (1H, t, *J* = 7.9 Hz), 5.18 (1H, s), 4.46 (2H, d, *J* = 5.6 Hz), 4.24 (2H, t, *J* = 7.0 Hz), 1.80--1.59 (2H, m), 1.14 (16H, s), 0.78 (3H, t, *J* = 6.9 Hz) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.1 (C=O), 153.0 (C), 152.7 (C), 143.1 (C), 131.6 (CH), 123.1 (CH), 122.8 (CH), 122.3 (CH), 116.7 (CH), 114.4 (C), 82.3 (CH), 49.2 (CH~2~), 37.7 (CH~2~), 31.0 (CH~2~), 29.4 (CH~2~), 28.7 (CH~2~), 28.6 (CH~2~), 28.6 (CH~2~), 28.4 (CH~2~), 28.1 (CH~2~), 25.6 (CH~2~), 21.8 (CH~2~), 13.6 (CH~3~) ppm; EIMS *m*/*z* 396 (\[M^+^\], 88); 395 (16); 368 (40); 367 (100); 339 (15); 297 (18); 283 (17); 235 (20); 227 (37); 199 (23); 198 (21); 162 (19); 57 (19); 55 (23); HREIMS 396.2504 (calcd. for C~23~H~32~N~4~O~2~ \[M^+^\] 396.2525); FT-IR (ATR) ν~max~ 3523, 3399, 3325, 3127, 3069, 2955, 2920, 2849, 1679, 1607, 1553, 1481, 1465, 1446, 1376, 1096, 1055 cm^−1^.

*4-(((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9l**). Following the experimental procedure described in method B, from 56.1 mg (0.28 mmol) of azidomethyl-benzene and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 45.5 mg (91%) of compound **9l** were obtained as an amorphous white solid. m.p. 217--219 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.03 (2H, d, *J* = 8.7 Hz), 7.96 (1H, dd, *J* = 8.0, 1.2 Hz), 7.50 (1H, t, *J* = 7.8 Hz), 7.31--7.19 (7H, m), 5.50 (2H, s), 5.19 (1H, s), 4.47 (2H, d, *J* = 5.8 Hz) ppm; ^13^C-NMR (125 MHz, (CD~3~)~2~SO) δ 161.2 (C=O), 153.0 (C), 152.8 (C), 143.5 (C), 135.9 (C), 131.7 (CH), 128.5 (2CH), 127.9 (CH), 127.7 (2CH), 123.2 (CH), 123.1 (CH), 122.3 (CH), 116.7 (CH), 114.3 (C), 82.4 (CH), 52.7 (CH~2~), 37.6 (CH~2~) ppm; EIMS *m*/*z* 332 (\[M^+^\], 41); 303 (14); 213 (18); 144 (13); 91 (100); 65 (11); HREIMS 332.1279 (calcd. for C~19~H~16~N~4~O~2~ \[M^+^\] 332.1273); FT-IR (ATR) ν~max~ 3283, 3141, 3075, 2922, 2852, 2366, 2323, 1697, 1608, 1557, 1482, 1446, 1380, 1322, 1262, 1222, 1188, 1124, 1058, 955, 920, 861, 827 cm^−1^.

*4-(((1-Tetradecyl-1H-1,2,3-triazol-4-yl)methyl)amino)-2H-chromen-2-one* (**9m**). Following the experimental procedure described in method B, from 68.0 mg (0.28 mmol) of 1-azido-tetradecane and 28 mg (0.14 mmol) of *N*-propargylated coumarin (**6**), 63.5 mg (96%) of compound **9m** were obtained as an amorphous white solid. m.p. 156--157 °C; ^1^H-NMR (500 MHz, (CD~3~)~2~SO) δ 8.23 (1H, t, *J* = 5.7 Hz), 8.07 (1H, s), 8.05 (1H, d, *J* = 8.1 Hz), 7.58 (1H, d, *J* = 7.5 Hz), 7.33--7.29 (2H, m), 5.24 (1H, s), 4.53 (2H, d, *J* = 5.7 Hz), 4.31 (2H, t, *J* = 7.0 Hz), 1.75 (2H, t, *J* = 7.3 Hz ), 1.23--1.13 (22H, m), 0.85 (3H, t, *J* = 6.9 Hz) ppm; ^13^C-NMR (150 MHz, (CD~3~)~2~SO) δ 161.8 (C=O), 153.5 (C), 153.3 (C), 143.7 (C), 132.4 (CH), 123.8 (CH), 123.5 (CH), 122.9 (CH), 117.4 (CH), 114.9 (C), 82.8 (CH), 49.7 (CH~2~), 31.7 (CH~2~), 30.1 (CH~2~), 29.5 (2CH~2~), 29.4 (2CH~2~), 29.3 (2CH~2~), 29.1 (CH~2~), 28.7 (CH~2~), 26.2 (CH~2~), 22.5 (CH~2~), 14.4 (CH~3~) ppm; EIMS *m*/*z* 438 (\[M^+^\], 92); 410 (55); 409 (100); 367 (37); 227 (51); 199 (44); 198 (60); 162 (39); 57 (42); 55 (47); HREIMS 438.2978 (calcd. for C~26~H~38~N~4~O~2~ \[M^+^\] 438.2995); FT-IR (ATR) ν~max~ 3320, 3127, 3070, 2918, 2848, 2416, 2167, 2051, 1983, 1658, 1606, 1550, 1467, 1377, 1322, 1258, 1202, 1150, 1118, 1055, 966, 938, 867, 835 cm^−1^.

3.2. Microbial Strains {#sec3dot2-molecules-23-00199}
----------------------

*Staphylococcus aureus* (ATCC 6538), *Enterococcus faecalis* (PCM 2673), *Escherichia coli* (ATCC 8739), *Klebsiella pneumoniae* (PCM1, *Pseudomonas aeruginosa* (PCM 2562) and yeast *Candida albicans* (ATCC 10231) were obtained from the Department of Molecular Biology, The John Paul II Catholic University of Lublin, Poland.

3.3. MIC Determination {#sec3dot3-molecules-23-00199}
----------------------

The in vitro antimicrobial studies were carried out with the microbroth dilution method against test organisms, as described previously \[[@B59-molecules-23-00199],[@B60-molecules-23-00199]\]. The bacterial strains were inoculated in Mueller Hinton Broth medium (Biocorp, Warsaw, Poland) and the *Candida* strain was inoculated in Sabouraud Dextrose liquid medium (Biocorp, Poland) and incubated at 37 °C and at 30 °C, respectively, with vigorous shaking (200 rpm) for 24 h. Bacterial cell suspensions at initial inoculums of 5 × 10^5^ in Mueller-Hinton liquid medium and adequate yeast suspensions at initial inoculums of 3 × 10^3^ cfu/mL in Sabouraud Dextrose Broth were exposed to the examined compound at relevant concentrations (range 0.001--2 mg/mL) for 24 h at 37 °C for the bacteria and for 48 h at 30 °C in the case of the fungi. Simultaneously, the standard antibiotics, chloramphenicol for antibacterial activity and ketoconazole for antifungal activity (as a positive control), were tested against the pathogens. The MIC was the lowest concentration of the compounds that inhibited the visible growth of the microorganism. The experiments were performed in triplicate.

3.4. Haemolytic Assay {#sec3dot4-molecules-23-00199}
---------------------

Haemolytic properties of the selected compounds were determined according to the method described previously \[[@B45-molecules-23-00199]\]. The human blood samples were centrifuged at 500× *g* for 10 min at 4 °C and the supernatant was discarded. Next, the erythrocytes were resuspended with PBS buffer (10 mM phosphate, pH 7.5; 150 mM NaCl) and centrifuged as previously. The washing procedure was repeated until a transparent supernatant was obtained. The washed erythrocytes were finally resuspended in PBS buffer to a final concentration of 2%. Simultaneously, appropriate concentrations (5, 10, 25, 50, 100 and 500 µg/mL for **8a**, **8f**, **9h** and **9k**, or 2, 5, 12.5, 50, 125 and 250 µg/mL for **8b**) of the examined compounds were prepared in a final volume of 50 mL DMSO. The compounds prepared in this way were mixed with 450 mL of 2% erythrocyte suspension and incubated for 1 h at 37 °C. Then, the samples were centrifuged at 5000× *g* for 10 min and absorbance at wavelength 415 nm was measured.

4. Conclusions {#sec4-molecules-23-00199}
==============

In conclusion, twenty-eight coumarin-triazole conjugates were synthesized through a copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition reaction of the corresponding *O*-propargylated coumarin (**3**) or *N*-propargylated coumarin (**6**) with alkyl or aryl azides. Five of them (**8a**, **8b**, **8f**, **9h** and **9k**) displayed promising activity against *Enterococcus faecalis* at MICs ranging from 12.5 to 50.0 µg/mL. Compound **8b** having a 2-OMe-Ph group attached at the triazol nucleus and an --OCH~2~-- linker was the best of the series. The most active compounds showed minimal toxicity towards human blood cells.
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![Formation of *O*-propargylated coumarin (**3**) and *N*-propargylated coumarin (**6**).](molecules-23-00199-sch001){#molecules-23-00199-sch001}

![Formation of 4-substituted 1,2,3-triazole-coumarin derivatives **8** and **9**.](molecules-23-00199-sch002){#molecules-23-00199-sch002}

![Preparation of azides **7a**--**7j**.](molecules-23-00199-sch003){#molecules-23-00199-sch003}

![Preparation of azides **7k**--**7m**.](molecules-23-00199-sch004){#molecules-23-00199-sch004}

###### 

Structures of 4-substituted 1,2,3-triazole-coumarin derivatives (**8a**--**8n**) and (**9a**--**9n**).

![](molecules-23-00199-g001a)

![](molecules-23-00199-g001b)

![Haemolytic activity of compounds **8a**, **8b**, **8f**, **9h** and **9k**. Tetracycline (TET) and chloramphenicol (CAM) in MIC concentrations were used as a control.](molecules-23-00199-g002){#molecules-23-00199-f002}

molecules-23-00199-t001_Table 1

###### 

Synthesized azides **7a**--**7j**.

  Entry   Azide    Ar               Yield ^a^
  ------- -------- ---------------- -----------
  1       **7a**   Ph               58
  2       **7b**   2-OMe--Ph        61
  3       **7c**   3-OMe--Ph        97
  4       **7d**   4-OMe--Ph        96
  5       **7e**   3-F, 4-OMe--Ph   96
  6       **7f**   4-F--Ph          41
  7       **7g**   3-CF~3~--Ph      31
  8       **7h**   3-NO~2~--Ph      82
  9       **7i**   5-*1H*-indol     35
  10      **7j**   3-furyl          \- ^b^

^a^ Isolated yield; ^b^ It was not isolated but was reacted in situ.

molecules-23-00199-t002_Table 2

###### 

Synthesized azides **7k**--**7m**.

  Entry   Azide    R                  Yield ^a^
  ------- -------- ------------------ -----------
  1       **7k**   (CH~2~)~10~CH~3~   86
  2       **7l**   (CH~2~)~13~CH~3~   73
  3       **7m**   CH~2~Ph            82

^a^ Isolated yield; ^b^ MW irradiation at 120 °C for 35 min was used.

molecules-23-00199-t003_Table 3

###### 

Antimicrobial activity (MIC µg/mL) of the synthesized compounds.

  Compound   *Candida albicans*   *Staphylococcus aureus*   *Enterococcus faecalis*   *Escherichia coli*   *Klebsiella pneumoniae*   *Pseudomonas aeruginosa*
  ---------- -------------------- ------------------------- ------------------------- -------------------- ------------------------- --------------------------
  **8a**     1600                 400                       50                        1600                 \-                        1600
  **8b**     800                  200                       12.5                      1600                 1600                      1600
  **8c**     1600                 800                       100                       1600                 800                       1600
  **8d**     \-                   \-                        200                       1600                 800                       1600
  **8e**     400                  400                       100                       200                  800                       800
  **8f**     1600                 1600                      50                        1600                 400                       800
  **8g**     800                  1600                      100                       800                  400                       800
  **8h**     800                  400                       400                       1600                 800                       1600
  **8i**     1600                 1600                      200                       1600                 1600                      1600
  **8j**     1600                 800                       800                       1600                 1600                      1600
  **8k**     \-                   \-                        400                       1600                 1600                      1600
  **8l**     \-                   \-                        400                       1600                 1600                      800
  **9a**     1600                 1600                      400                       1600                 1600                      \-
  **9b**     \-                   1600                      800                       1600                 800                       1600
  **9c**     200                  800                       400                       1600                 1600                      800
  **9d**     200                  400                       100                       800                  800                       800
  **9e**     200                  200                       100                       800                  800                       800
  **9f**     200                  \-                        1600                      1600                 1600                      \-
  **9g**     \-                   200                       \-                        \-                   \-                        \-
  **9h**     1600                 100                       50                        800                  800                       800
  **9i**     1600                 1600                      100                       1600                 800                       1600
  **9j**     \-                   800                       800                       1600                 1600                      \-
  **9k**     1600                 200                       50                        \-                   \-                        \-
  **9l**     1600                 \-                        800                       1600                 1600                      1600
  **CAM**    n.d.                 5                         5                         1.2                  5                         5
  **KET**    8                    n.d.                      n.d.                      n.d.                 n.d.                      n.d.

no activity; n.d.---not determined, CAM---chloramphenicol; KET---ketoconazole.
